If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

8th December, 2021

NOVELTY 2-year extension study announced

Home > News > NOVELTY 2-year extension study announced

We are pleased to announce that an extension period is planned for the NOVELTY study, in which a subset of approximately 3,000 patients will continue to be followed for up to an additional 2 years following completion of the main 3-year study. This extension period will enable further assessment of longitudinal patterns and more extensive evaluation of the disease trajectory in a smaller patient cohort, as well as provide a unique opportunity for pre- and post-COVID comparison.

As a global, observational, real-world study, NOVELTY is ideally placed to assess the impact of the COVID-19 pandemic on patients with obstructive lung disease. This planned extension period will describe and compare the effect of COVID-19 on patient behaviours, respiratory disease burden and disease progression in patients with asthma and/or COPD.

Additionally, the extension period will explore the major criteria by which physicians currently assign disease severity in patients with obstructive lung disease, as well as assess patients’ perception of their disease severity.



You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study